CatalystFDA/Bio

Lakefront sells early-stage CAR-T programs to Armed Cell Therapeutics

Lakefront divests early-stage CAR-T programs to Armed Cell Therapeutics.

What changed

Lakefront divests early-stage CAR-T programs to Armed Cell Therapeutics.

Why it matters

Lakefront divests early-stage CAR-T programs to Armed Cell Therapeutics. — impact context not separately stored; see What changed.

Sources